6-溴-1-(四氢-2H-吡喃-2-基)-1H-吡唑并[4,3-B]吡啶 | 1416713-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 6-溴-1-(四氢-2H-吡喃-2-基)-1H-吡唑并[4,3-B]吡啶
• 英文名称: 6-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine
• 英文别名: 6-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine；6-bromo-1-(oxan-2-yl)pyrazolo[4,3-b]pyridine
• CAS: 1416713-01-3
• 化学式: C₁₁H₁₂BrN₃O
• 分子量: 282.14
• InChiKey: SCRSCJLITQRXRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-溴-1-(四氢-2H-吡喃-2-基)-1H-吡唑并[4,3-B]吡啶 在 2-双环己基膦-2',6'-二甲氧基联苯 、 sodium tetrahydroborate 、 potassium phosphate 、 nickel (II) chloride hexahydrate 、 palladium diacetate 作用下， 以 甲醇 、 水 、 叔丁醇 为溶剂， 反应 17.0h， 生成 tert-butyl ((1-(tetrahydro-2H-pyran-2-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridin-6-yl)methyl)carbamate
  参考文献：
  名称：

  TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD

  摘要：

  The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.

  公开号：

  WO2023122783A2
• 作为产物：
  描述：

  3,4-二氢-2H-吡喃 、 6-溴-1H-吡唑并[4,3-b]吡啶 在 4-甲基苯磺酸吡啶 作用下， 以 四氢呋喃 为溶剂， 以63.8 %的产率得到6-溴-1-(四氢-2H-吡喃-2-基)-1H-吡唑并[4,3-B]吡啶
  参考文献：
  名称：

  PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS

  摘要：

  This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.

  公开号：

  WO2024044098A2

文献信息

• PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS
  申请人：[en]ALEXION PHARMACEUTICALS, INC.

  公开号：WO2024044098A2

  公开（公告）日：2024-02-29

  This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.
• TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD
  申请人：[en]THE KATHOLIEKE UNIVERSITEIT LEUVEN

  公开号：WO2023122783A2

  公开（公告）日：2023-06-29

  The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.